Albiglutide

DB09043ApprovedInvestigationalWithdrawnProtein Based TherapiesBlood Glucose Lowering Agents GLP-1 Agonists

Albiglutide is a GLP-1 agonist used to manage type 2 diabetes mellitus. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline).

Protein structure of Albiglutide

Mechanism: Albiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.
Curator reviewed
Primary indication: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Curator reviewed · 1 structured indication
Formula / weight: C₃₂₃₂H₅₀₃₂N₈₆₄O₉₇₉S₄₁ · 72970.0 Da
First approval: Canada, 2015 · United States, 2014
Code names: GSK-716155

Resolves to

Compound

UNII5E7U48495ECAS782500-75-8KEGGD08843

Clinical / RWD

RxNorm1534763ATCA10BJ04

Targets

P43220GLP1R

What you can answer from here — as of September 14, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

609Drug interactionsStructured to mechanism, not free text

16Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

12Marketed productsAcross 4 countries and 2 labellers

1ATC codeIncluding every combination product, plus 13 drug categories

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Albiglutide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In